CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00351-06v1
14/3/331    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haynes, L. M.
Right arrow Articles by Anderson, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haynes, L. M.
Right arrow Articles by Anderson, L. J.

 Previous Article

Clinical and Vaccine Immunology, March 2007, p. 331-333, Vol. 14, No. 3
1071-412X/07/$08.00+0     doi:10.1128/CVI.00351-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid Proteins{triangledown}

Lia M. Haynes,1* Congrong Miao,1 Jennifer L. Harcourt,1 Joel M. Montgomery,2 Mai Quynh Le,7 Sergey A. Dryga,5 Kurt I. Kamrud,5 Bryan Rivers,5 Gregory J. Babcock,6 Jennifer Betts Oliver,2 James A. Comer,2 Mary Reynolds,3 Timothy M. Uyeki,4 Daniel Bausch,2 Thomas Ksiazek,2 William Thomas,6 Harold Alterson,5 Jonathan Smith,5 Donna M. Ambrosino,6 and Larry J. Anderson1

National Centers for Immunization and Respiratory Diseases, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Branch,1 Division of Viral and Rickettsial Diseases, Special Pathogens Branch,2 Poxvirus Activity,3 Influenza Division, Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd. NE, Atlanta, Georgia,4 AlphaVax, Inc., Research Triangle Park, North Carolina,5 Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, Massachusetts,6 National Institute of Hygiene and Epidemiology, Hanoi, Vietnam7

Received 26 September 2006/ Returned for modification 31 October 2006/ Accepted 8 January 2007

Recombinant severe acute respiratory syndrome (SARS) nucleocapsid and spike protein-based immunoglobulin G immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to the SARS coronavirus in sera collected from patients as late as 2 years postonset of symptoms. These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies.

* Corresponding author. Mailing address: Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop G-18, Atlanta, GA 30333. Phone: (404) 639-4004. Fax: (404) 639-4005. E-mail: loh5{at}cdc.gov.

{triangledown} Published ahead of print on 17 January 2007.

Clinical and Vaccine Immunology, March 2007, p. 331-333, Vol. 14, No. 3
1071-412X/07/$08.00+0     doi:10.1128/CVI.00351-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.